Fundsmith LLP Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Fundsmith LLP bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 127,537 shares of the company's stock, valued at approximately $42,372,000. Fundsmith LLP owned about 0.41% of Medpace as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Medpace by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock valued at $854,087,000 after purchasing an additional 25,704 shares in the last quarter. Invesco Ltd. increased its stake in shares of Medpace by 91.8% in the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock worth $360,387,000 after acquiring an additional 519,186 shares during the period. Wasatch Advisors LP increased its stake in shares of Medpace by 3.1% in the fourth quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock worth $311,247,000 after acquiring an additional 28,161 shares during the period. Geode Capital Management LLC increased its stake in shares of Medpace by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock worth $218,031,000 after acquiring an additional 28,076 shares during the period. Finally, Bessemer Group Inc. increased its stake in shares of Medpace by 15.0% in the fourth quarter. Bessemer Group Inc. now owns 576,044 shares of the company's stock worth $191,379,000 after acquiring an additional 75,275 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Down 1.6%

MEDP traded down $4.78 during midday trading on Friday, hitting $296.03. 199,914 shares of the company traded hands, compared to its average volume of 346,768. The company has a market capitalization of $8.51 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77. The business has a 50 day simple moving average of $306.90 and a two-hundred day simple moving average of $328.59.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period last year, the firm posted $3.20 earnings per share. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of research reports. Truist Financial cut their price objective on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Mizuho dropped their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Finally, TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and dropped their price target for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, Medpace presently has an average rating of "Hold" and an average price target of $349.30.

Insider Buying and Selling at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the transaction, the director now directly owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.